Pharmaceutical Power Articles & Analysis: Older
6 articles found
Reduction of total organic carbon (TOC) is critical for a number of industries who use ultrapure water, such as microelectronics, pharmaceuticals and power industries. UV applications in microelectronics includes UV disinfection, TOC reduction, chlorine & chloramines reduction and ozone reduction. As critical dimensions for integrated circuits continue to decrease, transistor capacities ...
Visit us at USA Pavilion Stand 615SnowPure Water Technologies is in the prime position in the USA Pavilion at the upcoming 2019 Aquatech Mexico Exhibition in Mexico City. Please stop by our booth to see Dr. Michael Snow (President), Janell Cedarstrom (International Sales Manager), and Eduardo Campos (Sales).Dr. Michael Snow will take to the Aquastage along with other industry leaders on ...
This week is the largest water exhibition in the world — Aquatech China 2018. SnowPure is part of this, and you can find us in Hall 8, Floor 1, Stand H738. (8.1.H738). Electropure China is co-located with Shanghai Yuan Mai Environmental Technology this year. We will be exhibiting the wide range of electrodeionization products produced, aimed at Chinese power plants, pharmaceutical ...
nduramaxx is pleased to announce that they are now fully registered as a supplier on the Achilles UVDB Community (Utilities Vendor Database). Achilles UVDB is a business community for the UK utilities industry and major contractors enabling the sector to use the Achilles supplier pre-qualification system to manage risk and comply with EU procurement regulations. Achilles provides a fair, open ...
In order to contain expenditures for pharmaceuticals, the latest healthcare reforms have focused on decentralising German pharmaceutical market. Health insurance funds are now able to tender the products and subsequently conclude rebate contracts with one or more companies. Considering the enormous bargaining power of health insurance funds, pharmaceutical manufacturers, in particular companies ...
The pharmaceutical industry remains powerful due to its firm scale and global reach. However, analysis of the source of biotechnology-derived products in healthcare, valued at $70 billion worldwide by 2000, reveals an almost complete dependence, in three key markets of the USA, UK and Germany, on products developed by entrepreneurial biotechnology firms. These tend to operate in knowledge-driven ...